Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Absorbing Debate: Boston Sci, Abbott Differ On Whether The Future Of Stents Is To Disappear

This article was originally published in The Gray Sheet

Executive Summary

Competing visions of the future of percutaneous coronary interventions were on display at TCT year, with Boston Scientific pushing its Synergy bioabsorbable polymer-coated, drug-eluting metal stent platform as the better long-term option to fully-resorbable scaffolds of the type Abbott is first out of the gate with.

Advertisement

Related Content

Abbott Launches First Fully Absorbing Stent In US Market
FDA Briefing Docs Appear Positive For Abbott's Absorb, But Adverse Events Highlighted
Abbott’s Absorb GT1 Bioresorbable Scaffold Gets FDA Panel Date
In Case You Missed It: Top 10 "Gray Sheet" Stories In October
Boston Sci Says It Will Be Careful About Resorbable Scaffold Investment
Abbott Submits PMA For Absorb Bioresorbable Scaffold
New Product Briefs
Reinvigorating The Coronary Stent Market: Can Bioresorbable Scaffolds Do The Job?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register